Endoscopic sphincterotoMy for delayIng choLecystectomy in mild acute biliarY pancreatitis (EMILY study): Protocol of a multicentre randomised clinical trial by Kucserik, Levente Pál et al.
1Kucserik LP, et al. BMJ Open 2019;9:e025551. doi:10.1136/bmjopen-2018-025551
Open access 
Endoscopic sphincterotoMy for 
delayIng choLecystectomy in mild acute 
biliarY pancreatitis (EMILY study): 
protocol of a multicentre randomised 
clinical trial
Levente Pál Kucserik,1 Katalin Márta,2,3 Áron Vincze,2,4 György Lázár,5 
László Czakó,6 Zsolt Szentkereszty,7 Mária Papp,8 Károly Palatka,8 Ferenc Izbéki,9 
Áron Altorjay,10 Imola Török,11 Sorin Barbu,12 Marcel Tantau,12 András Vereczkei,13 
Lajos Bogár,14 Márton Dénes,15 Imola Németh,16 Andrea Szentesi,17,18 
Noémi Zádori,2 Judit Antal,2 Markus M Lerch,19 John Neoptolemos,20 
Miklós Sahin-Tóth,21 Ole H Petersen,22 Dezső Kelemen,23 Péter Hegyi  2,24
To cite: Kucserik LP, Márta K, 
Vincze Á, et al.  Endoscopic 
sphincterotoMy for delayIng 
choLecystectomy in mild 
acute biliarY pancreatitis 
(EMILY study): protocol of 
a multicentre randomised 
clinical trial. BMJ Open 
2019;9:e025551. doi:10.1136/
bmjopen-2018-025551
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
025551). 
DK and PH contributed equally.
Received 1 August 2018
Revised 20 March 2019
Accepted 2 May 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Péter Hegyi;  
 p. hegyi@ tm- centre. org
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction According to the literature, early 
cholecystectomy is necessary to avoid complications 
related to gallstones after an initial episode of acute biliary 
pancreatitis (ABP). A randomised, controlled multicentre 
trial (the PONCHO trial) revealed that in the case of 
gallstone-induced pancreatitis, early cholecystectomy 
was safe in patients with mild gallstone pancreatitis 
and reduced the risk of recurrent gallstone-related 
complications, as compared with interval cholecystectomy. 
We hypothesise that carrying out a sphincterotomy 
(ES) allows us to delay cholecystectomy, thus making it 
logistically easier to perform and potentially increasing the 
efficacy and safety of the procedure.
Methods/Design EMILY is a prospective, randomised, 
controlled multicentre trial. All patients with mild ABP, 
who underwent ES during the index admission or in the 
medical history will be informed to take part in EMILY 
study. The patients will be randomised into two groups: 
(1) early cholecystectomy (within 6 days after discharge) 
and (2) patients with delayed (interval) cholecystectomy 
(between 45 and 60 days after discharge). During 
a 12-month period, 93 patients will be enrolled 
from participating clinics. The primary endpoint is a 
composite endpoint of mortality and recurrent acute 
biliary events (that is, recurrent ABP, acute cholecystitis, 
uncomplicated biliary colic and cholangitis). The 
secondary endpoints are organ failure, biliary leakage, 
technical difficulty of the cholecystectomy, surgical and 
other complications.
Ethics and dissemination The trial has been registered 
internationally ISRCTN 10667869, and approved by the 
relevant organisation, the Scientific and Research Ethics 
Committee of the Hungarian Medical Research Council 
(EKU/2018/12176–5).
trial registration number ISCRTN 10667869; Pre-
results.
IntroDuCtIon
Acute pancreatitis is one of the leading 
gastrointestinal causes of acute hospital 
admissions.1 2 In most cases, it is caused by 
gallstones or oedema.3 Gallstone-induced 
pancreatitis involves a pathophysiological 
factor, namely a distal common channel of 
strengths and limitations of this study
 ► The study is designed as a prospective, ran-
domised-controlled trial to achieve conclusion on the 
highest evidence level to provide the first evidence 
concerning the possible benefits of sphincterotomy 
(ES) on timing cholecystectomy, it is (i) multinational, 
(ii) multicentric, (iii) internationally registered and (iv) 
the prestudy protocol is published.
 ► Only high volume, expert centres can join to the 
study. They have to provide (i) laparoscopically 
trained surgeons with  >100 laparoscopic proce-
dures performed and (ii) if  endoscopic retrograde 
cholangiopancreatography  (ERCP)/ES is provided 
during the index admission, trained gastroenterol-
ogist with >50 ES completed within a year must be 
on duty.
 ► The study enjoys continuous support from (i) an 
International Translational Advisory Board including 
top, well-established experts from different area of 
research field (ii) an Independent Data Management 
Board.
 ► The final conclusion can be achieved with low num-
ber of patients within a relatively short period of 
time.
 ► The study will provide evidence in a selected pop-
ulation (mild acute biliary pancreatitis (ABP) who 
underwent ERCP+ES) and no evidence concerning 
the usefulness of ES in moderate and severe ABP.
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the biliary and pancreatic ducts, which can be found in 
80% of acute biliary pancreatitis (ABP).4 ABP is a clin-
ical entity with high rates of morbidity (15%–50%) and 
mortality (2%-5%).5 After ABP, several complications may 
occur; recurrent acute pancreatitis, cholestasis and fistula 
affecting the hepatobiliary system or other biliary events, 
such as acute cholecystitis, obstruction of the common 
biliary duct, cholangitis or biliary colic.6 7 Interval chole-
cystectomy after mild ABP is associated with a high risk 
of readmission for recurrent biliary events, especially 
after recurrent ABP.8 The international practice guide-
lines recommend that in case of cholangitis or choled-
ocholthiasis, an ERCP should be performed to clear 
the bile duct with endoscopic sphincterotomy (ES). In 
addition, cholecystectomy should also be performed to 
avoid complications related to recurrent biliary events.9 10 
In patients with clinically severe pancreatitis, with local 
complications, such as pancreatic necrosis or organ 
failure, the intervention, namely the laparoscopic chole-
cystectomy (LC), is delayed 6 months until complications 
are resolved.11 In cases of mild ABP, cholecystectomy is 
recommended between days 7 and 21.4 The latest studies 
show that after discharge of patients with ABP, cholecys-
tectomy could reduce the risk of a recurrent ABP and 
other gallstone-induced complications.12 In this setting, 
surgeons still prefer delayed cholecystectomy for efficacy 
and safety and for logistical reasons.13 Some publications 
draw attention to ERCP/ES, which could reduce mortality 
and the formation of severe biliary complications.3 14 The 
aim of the EMILY trial is to combine a surgical treatment 
and a gastroenterological procedure to investigate if ES 
with delayed cholecystectomy (within 45–60 days after 
discharge) compared with ES with early cholecystectomy 
(within 6 days after discharge) could reduce recurrent 
biliary events.
MEthoDs
Design
EMILY is a prospective, randomised-controlled, multi-
centre trial. The patients are randomised into two groups: 
(1) Patients who undergo early cholecystectomy (within 
6 days after discharge) and (2) patients who undergo 
delayed (interval) cholecystectomy (between 45 and 
60 days after discharge). During a 12-month period, 93 
patients will be enrolled from participating clinics. The 
primary endpoint is a composite endpoint of mortality 
and recurrent acute biliary events (which are recurrent 
ABP, acute cholecystitis, uncomplicated biliary colic and 
cholangitis). The secondary endpoints are: organ failure, 
biliary leakage, technical difficulty of cholecystectomy 
and surgical and other complications.
This study was structured following the SPIRIT 
201315 guideline defining standard protocol items for 
clinical trials and got the relevant ethical approval 
EKU/2018/12176–5 (Scientific and Research Ethical 
Committee, Medical Research Council, Hungary).
trial organisation, committees and boards
The coordinator and designer of the EMILY study is 
the Centre for Translational Medicine at the Univer-
sity of Pécs Medical School (coordinating institution and 
sponsor, http://www. tm- centre. org) and the Hungarian 
Pancreatic Study Group (HPSG-coordinating society, 
http://www. pancreas. hu). The HPSG was established in 
2011 to stimulate research in pancreatic diseases.
Until now, it has launched three international obser-
vational clinical studies in 201416–18 (EASY, APPLE 
and PINEAPPLE) and two interventional studies 
(PREPAST19—2014 and GOULASH20—2017) and has 
published the relevant guidelines for pancreatic diseases 
to improve patient care in pancreatology.21–24
The following committees and boards will be 
involved: Steering Committee (SC): The committee will 
be led by PH (corresponding investigator, gastroenterolo-
gist and internal medicine specialist).
The members in Szeged (HU) will be: LC (gastroen-
terologist), GL (surgeon); Debrecen (HU): MP (gastro-
enterologist), KP (gastroenterologist), ZS (surgeon); 
Pécs (HU): ÁV (gastroenterologist), DK (surgeon), AV 
(surgeon), LB (anaesthesiologist), DK (surgeon), PH 
(gastroenterologist); Székesfehérvár (HU): FI (gastroen-
terologist), ÁA (surgeon); Targu Mures (RO): IT (gastro-
enterologist), LPK (surgeon), MD (surgeon), Cluj Napoca 
(RO): BS (surgeon), TM (gastroenterologist). KM, ZN 
and JA are trial management specialists, IN (statistician), 
whereas AS leads the multidisciplinary core facility which 
will assist the scientists to run the study successfully. The 
SC will make decisions concerning all relevant questions 
including drop outs during the study.
International Translational Advisory Board (ITAB): The 
board will consist of a gastroenterologist (MML), a 
surgeon and two basic scientists (JN, MST, OHP). The 
ITAB will continuously monitor the progress of the study 
and will advise the SC.
The study was designed by the SC and ITAB. It was 
funded by the University of Pécs, Medical School. The 
sponsor was not involved in the design of the study and 
will have no access to database or the randomisation code.
The study also contains an independent physician and 
safety manager as required by the ethical regulation.
study population
All patients with mild ABP (according to the revised 
Atlanta classification25) will be informed of the possibility 
to take part in the EMILY trial. After the consent form is 
signed, participants will be randomised into two groups 
if they meet all the inclusion and no exclusion criteria 
(figure 1).
Inclusion criteria
The criteria for inclusion in the study are: (1) patients older 
than 18 years of age; (2) diagnosis of acute pancreatitis (at 
least two of the following three symptoms: upper abdominal 
pain, serum lipase or amylase is three times higher than the 
upper limit of normal and characteristic findings for acute 
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pancreatitis on imaging); (3) the presence of ABP (any of 
the following three definitions): diagnosis of gallstones on 
imaging and alanine aminotransferase level >2 times higher 
than normal values with ALT>AST; (4) mild ABP (meaning 
no pancreatic necrosis, no transient or persistent organ 
failure (>48 hours) is present; (5) ERCP/ES either during 
the index admission or in the medical history without compli-
cation; (6) signed written informed consent (all included 
patient will sign the consent which contains the information 
about the trial and procedures) (figure 1).
Exclusion criteria
A patient’s bad physical status can be an exclusion criterion. 
American Society of Anesthesiologists (ASA) III patients>75 
years old; ASA IV or V patients, will be excluded. Patients 
with continuous alcohol abuse, acute or chronic cholecys-
titis during hospitalisation, chronic pancreatitis, pregnancy, 
previous cholecystectomy will also be excluded (figure 1).
time of randomisation
Five criteria are described by the PONCHO trial.26 If 
these five criteria are met, the informed consent will be 
signed by the patient and a control abdominal CT will 
be carried out before discharge. These criteria are the 
following: (1) anticipation on the part of the treating 
physician that the patient can be discharged; (2) the 
patient has no abdominal pain and there is no need 
for analgesics; (3) declining C reactive protein levels 
and <150 mg/L; (4) no evidence of local or systemic 
complications (eg, no fever); (5) oral feeding is toler-
ated for 24 hours. The patient must be randomised on 
the day of the discharge.
randomisation
The method of randomisation is the following: The 
patient can be randomised by the study coordinator 
using a randomisation module with sealed envelope. 
Patient data will be uploaded with the help of the admin-
istrator to the database, which will be followed by the 
randomisation. This randomisation module will allo-
cate the participants to the two different groups. This 
method makes it impossible for researchers to predict 
the allocation of the patients involved in the study. It is 
impossible to conceal the distribution of the patients in 
this study because the patients need to be scheduled for 
either an early cholecystectomy or a delayed cholecys-
tectomy (figure 1).
Allocation will be carried out based on predefined 
randomisation lists created separately for each recruiting 
centre. The allocation sequence will be prepared with a 
variable block size by an allocation ratio 1:1 by the Inde-
pendent Data Management Board (IDMB).
blinding
In prevention of patient’s selection to group A and B trial 
participants, care providers and outcome assessors will be 
Figure 1 The flowchart of participants according to SPIRIT 2013 guideline.15 *No pancreatic necrosis, no transient or 
persistent organ failure (>48 hours) is present with any of the following three definitions: (1) diagnosis of gallstones on imaging, 
(2) alanine aminotransferase level >2 times higher than normal values with ALT >AST. †ASA IV or V patients and ASA III>75 
years old. ABP, acute biliary pancreatitis; ASA, American Society of Anesthesiologists; CRP, C reactive protein; ES, endoscopic 
sphincterotomy. 
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blinded until the allocation, as no access to randomisation 
sequence. From assignment to intervention blinding cannot 
be provided considering the study characteristics (exact date 
of cholecystectomy). The allocation sequence is unblinded 
only to data analysts who are completely independent form 
medical team (decision making) and data collection.
Endpoints
Primary endpoint
The primary endpoint is a composite endpoint, which is 
based on mortality and on recurrent biliary events (which 
are recurrent ABP, acute cholecystitis, uncomplicated 
biliary colic and cholangitis). The observation period 
is 3 months. We decide based on criteria in figure 2 if a 
complication is present or not.
secondary endpoints
We hypothesise that cholecystectomy for ABP between 
days 45–60 after discharge in patients with ES is as effec-
tive and safe as early cholecystectomy (within 6 day after 
discharge). In order to evaluate this, we will observe the 
following parameters: the number of biliary colic regis-
tered for the patient, difficulty of cholecystectomy (on 
a scale of 0–10, 0=easy, 5=moderately difficult, 10=hard, 
rate of conversion to open cholecystectomy, total length 
of hospital stay, need for intensive care unit (ICU) 
admission and total length of ICU stay, organ failure and 
biliary leakage (figure 2).
treatment protocol
Randomisation:
Group A. Early cholecystectomy
Group B. Delayed cholecystectomy
We randomise patients into two groups after discharge 
(figure 3):
Group A: The patient is randomised to the early cholecys-
tectomy group, and cholecystectomy will be performed 
within 6 days after discharge.
Group B: The patient is randomised to the delayed chole-
cystectomy group, and the cholecystectomy will be carried 
out between 45 and 60 days after discharge.
Discontinuing or the modification of the allocated 
interventions for a trial participant is based on surgical 
causes like contraindicated opus, need for conversion 
to open cholecystectomy or when the patient does not 
present to the hospital for cholecystectomy. Switching 
over the two interventions is not possible considering 
the trial characteristics; however, in case of acute chole-
cystitis, acute cholecystectomia can be performed inde-
pendently from this trial. The case must be presented 
to SC.
Figure 2 The evaluation of primary and secondary endpoints.30–33
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surgical details and quality control
If it will be the first ERCP/ES performed in the patient’s 
medical history, it will be performed according to 
the European Society of Gastrointestinal Endoscopy 
(ESGE) guidelines.27 The LC will follow the Euro-
pean Association Guidelines for Endoscopic Surgery.28 
The patients will be operated on by laparoscopi-
cally trained surgeons with >100 laparoscopic proce-
dures performed and by a trained gastroenterologist 
with >50 ES completed within a year must be on duty 
if ERCP/ES is provided during the index admission. 
Centres which intend to randomise at least 15 patients 
and are able to perform an early cholecystectomy and 
ERCP/ES are eligible to participate in the study. In 
those centres, ES data will then be collected on the 
incidence of choledocholithiasis, percentage bile duct 
injury, duration and perceived difficulty (on a scale of 
0–10).
Diagnosing and treating AbP
In the first 24 hours of admission, all patients will undergo 
either an ultrasonography or a contrast-enhanced CT to 
detect if the gallbladder contains gallstones and to determi-
nate the diameter of the common bile duct. ERCP should 
be performed only in the case of cholangitis or choledo-
cholthiasis, to clear the bile duct with ES as described in the 
IAP/APA guideline. When only the laboratory parameters 
Figure 3 Schedule of enrolment, interventions and assessments according to the SPIRIT 2013 statement.15 *Diagnosis 
of acute biliary pancreatitis (any of the following three definitions): diagnosis of gallstones on imaging, and alanine 
aminotransferase level >2 times higher than normal values with ALT >AST. In the first 24 hours of admission, all patients 
will undergo either an ultrasonography or a contrast-enhanced CT to detect if the gallbladder contains gallstones and to 
determinate the diameter of the common bile duct. ABP is mild, when there is no pancreatic necrosis or no transient or 
persistent organ failure (>48 hours). **If it is necessary to perform endoscopic sphincterotomy during the current admission or 
ES in the medical history also acceptable. ***Data will be collected in a personalised database and follow-up will consist of 
questionnaires. The patient will be asked to note every biliary event during the follow-up period and will be contacted in person 
within the 90 days after discharge to collect information. After data collection, we can draw conclusions about the treatment 
strategy. Improperly completed datasheets and incorrect data upload will be avoided and controlled by the administrator. (Q5, 
Q7, Q8, Q=question) **** The patient can be randomised by using a randomisation module with sealed envelope. Patient data 
will be uploaded to the data base, which will be followed by the randomisation. This randomisation module will allocate the 
participants to the two different groups. This method makes it impossible for researchers to predict the allocation of the patients 
involved in the study. It is impossible to conceal the distribution of the patients in this study because the patients need to be 
scheduled for either an early cholecystectomy or a delayed cholecystectomy. Allocation will be carried out based on predefined 
randomisation lists created separately for each recruiting centre. The allocation sequence will be prepared with a variable block 
size and with an allocation ratio 1:1 by the IDMB. *****The criteria are the following: (1) anticipation on the part of the treating 
physician that the patient can be discharged within 1 or 2 days; (2) no need for analgesics; (3) declining C reactive protein levels 
and <150 mg/L; (4) no evidence of local or systemic complications (eg, no fever); (5) oral feeding is tolerated for 24 hours and 
(6) ERCP/ES either during the index admission or in the medical history without complication. Before discharge or transfer to 
surgery department. ES, endoscopic sphincterotomy; IDMB, Independent Data Management Board.
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suggest common bile duct obstruction or choledocholthi-
asis, MRCP/EUS should be carried out.10
Data collection and follow-up
Data will be collected in a personalised database, and 
follow-up will consist of questionnaires (online supple-
mentary file). The patient will be asked to note every 
biliary event during the follow-up period and will be 
contacted in person within 90 days after discharge to 
collect information. After data collection, we can draw 
conclusions about the treatment strategy. Improperly 
completed datasheets and incorrect data upload will be 
avoided and controlled by an administrator.
The personal information about enrolled participants 
will only be shared with IDMB as uploaded data for rando-
misation, after data analysis only randomisation code 
will be used for identification to protect confidentiality 
during, and after the trial. Only the principal investigator 
and the IDMB will have access to the final trial dataset. 
However, only identification code is used, and we can 
keep aside duplicated patient’s data as cholecystectomy 
cannot be performed twice.
sample size estimation method
Primary endpoint
A composite of gallstone-related complications or 
mortality occurring within 6 months after discharge.
Hypothesis
With regard to our hypothesis, based on a non-inferiority 
design, there is no difference between the two groups 
(5%) in mortality or readmission for gallstone-related 
complications within 3 months after discharge.
Starting point
Sample size estimation was based on the results obtained 
by the PONCHO trial carried out on 264 patients, where 
a non-significant difference of 14% was obtained between 
the two study groups (3% in the same-admission cholecys-
tectomy group compared with 17% in the interval admis-
sion group). Thus, using the hypothesised 5% for the 
occurrence of the primary endpoint in the same-admis-
sion cholecystectomy group and a max difference of 14% 
given by the results of the PONCHO trial a total sample 
size of 93 was obtained using a 10% drop-out rate. The 
sample size estimation results are listed in figure 4.
Data management and statistical analyses
Data will be handled by an independent Clinical Research 
Organiser. Electronic case report form (eCRF) will be 
used. The Investigator will ensure that the data in the 
eCRF are accurate, complete and legible. Detailed data 
flow will be described in a Data Management Plan. Data 
from completed eCRFs will be validated under the direc-
tion of the Data Manager according to a Data Cleaning 
Plan (DCP). Adverse events will be coded using MedDRA 
according to GCP, GLP, FDA 21CFR PART11 and other 
relevant regulatory requirements.
Safety Analysis Set (all patients enrolled in the study), 
Per Protocol Set (all enrolled patients who finished 
the study conforming to the requirements of the study 
protocol) and Intention to Treat (all randomised partic-
ipants who start on a treatment, excluding consent with-
drawals) will be performed.
Baseline patient and disease characteristics will be 
analysed using descriptive analysis. Demographic and 
baseline characteristics will be summarised for the 
overall study population. Descriptive statistics for both 
the primary and secondary parameters will be analysed 
similarly.
Subgroup analyses will be performed concerning 
the imaging alterations: (1) no gallstones on imaging, 
(2) gallstone. Since we cannot exclude the possibility 
of fibrosis after earlier ES, we will perform a subgroup 
analysis during the interim analysis as well. If the results 
obtained from the interim analysis indicate that there 
could be significant difference between index admission 
and earlier ES, we will modify the trial protocol from 
the single-population (the same-admission endoscopic 
sphincterotomy or ES in the medical history) two-arm 
(two groups: (1) early cholecystectomy; (2) delayed 
cholecystectomy) set up to a two-population two-arm set 
up (four groups: (1) early or (2) delayed cholecystectomy 
with index admission ES, (3) early or (4) delayed chole-
cystectomy in patients having earlier ES). The required 
patients’ number will be adjusted in both populations 
accordingly. In case of important protocol modifications, 
IDMB will report to the SC. SC will discuss and if the 
adverse effect is confirmed, it will be reported to the rele-
vant institutional and national ethical committee http://
www. ett. hu/ tukeb. htm
Premature termination of the study
In the interests of patient safety, an interim analysis will 
be conducted after 15 patients and after half of the 
presumed number of patients (45) have completed the 
study. IDMB will perform an independent assessment of 
the trial related documents and activities, with the aim 
of ensuring the respect of subjects’ right, safety and well-
being and to guarantee the plausibility of clinical data. 
Similarity of groups at baseline will be also checked. The 
study will also be stopped if the two groups’ results differ 
significantly (p<0.001). The study will be discontinued if 
the difference between the planned number of patients 
and the actual number is higher than 60% within 1 year. 
IDMB will report to SC.
Centres
The trial will be launched in four Hungarian (Szeged, 
Debrecen, Pécs and Székesfehérvár) and two Romanian 
centres (Targu Mures and Cluj Napoca), after which the 
Figure 4 The listed parameters were used to estimate 
results for the current sample size.
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study will be open to other centres. In all cases, the IDMB 
will conduct an audit of the centre and will report to 
the SC. The SC maintains the right to decide whether a 
centre meets the required quality to join the study.
The full protocol will be available for public in an open 
access journal.
Publication policy
We would like to publish the results in one of the inter-
nationally highly recognised journals. Centres providing 
more than 25 patients can provide 4 authors to the 
authorship list: 2 surgeons and 2 gastroenterologists.
Patient and public involvement
This prestudy protocol contains no results and data, 
therefore patients and or public were not involved.
DIsCussIon
In the case of early LC, while dissection and logistics are 
more difficult6 7 compared with delayed (interval) chole-
cystectomy, it is still more effective. Delayed cholecystec-
tomy in a mild form of ABP is preferred by many surgeons, 
but a number of complications can occur: recurrent ABP, 
acute cholecystitis, obstruction of ductus choledochus 
and uncomplicated biliary colic.6 7 After ERCP/ES is 
performed, the common bile duct is cleared, the compli-
cations caused by gallstones are significantly reduced.29 
The EMILY study is designed to determine if ERCP/ES 
for mild ABP aids in delaying the cholecystectomy to day 
45–60 after discharge among patients with ABP.
If an ES aids in delaying a cholecystectomy, then we can 
reduce early cholecystectomy-related complications and 
the surgeons can proceed with a safer, easier cholecystec-
tomy using this method of treatment.
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